Physician profile

Adline Ghazi

Endocrinology, Diabetes & Metabolism · Washington, DC

NPI 1609033869

$4,525.16

in general payments reported to CMS, 2019-2025

27 companies · $247 in 2025

The $247 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

Payments by year

General and research payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,896.40
Travel and Lodging$936.75
Education$11.71

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Eli Lilly and Company $1,362.00 2022-2024
Novo Nordisk As $1,105.69 2019-2023
Lilly USA, LLC $553.87 2020-2024 Mounjaro, Humulin, Lyumjev
Novo Nordisk INC $240.49 2019-2025 Ozempic, Rybelsus
Boehringer Ingelheim Pharmaceuticals, INC. $198.01 2022-2024 Jardiance, Synjardy, Tradjenta
Corcept Therapeutics $163.32 2023-2025 Korlym
Radius Health, INC. $141.41 2022-2025 Tymlos
Dexcom, INC. $140.13 2021-2025 Dexcom G6 Transmitter
Tandem Diabetes Care, INC. $76.19 2022-2024 T:Slim X2 Insulin Pump With Control-Iq
Sanofi-Aventis U.S. LLC $69.39 2022-2023
Amgen INC. $65.84 2025 Evenity
Novartis Pharmaceuticals Corporation $55.15 2023-2024
Insulet Corporation $44.08 2021-2024 Omnipod
Abbott Laboratories $42.87 2022-2024 Freestyle Libre 3
Beta Bionics, INC. $42.74 2024 Ilet Bionic Pancreas
Show all 24 companies
CompanyGeneral paymentsYearsTop products
Medtronic, INC. $42.44 2021-2023 Minimed 780g
Becton, Dickinson and Company $39.20 2021
Embecta Corp. $33.20 2023 Bd Nano 2nd Gen Pen Needle
Medtronic Minimed, INC. $20.18 2020
Bayer Healthcare Pharmaceuticals INC. $18.84 2023
Xeris Pharmaceuticals, INC. $18.48 2023 Gvoke Hypopen
Nevro Corp. $17.68 2023 Senza
Alexion Pharmaceuticals, INC. $17.06 2024 Strensiq
Abbvie INC. $16.90 2021

3 companies reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$63,806.60 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Adline Ghazi

$4,525.16

in general payments reported 2019-2025

Years
2019-2025
Top company
Eli Lilly and Company
Context
The $247 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).

https://glasscript.com/doctor/72082/adline-ghazi

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.